Exhibit 99.1 Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results Q3 Revenue of $10.4 million Q3 Thyroid volume year-over-year increase of 7% Q3 Thyroid revenue year-over-year increase of 18% Trailing twelve-month thyroid revenue of $38.0 million, an increase of 13% on a comparable thyroid-only basis PARSIPPANY, NJ, November 16, 2026 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID: IDXG) today announced financial results for the third quarter ended September 30, 2026 and provided a business and financial update. Interpace generated Q3 2026 revenue of $10.4 million, up 18% year-over-year, a loss from continuing operations of $1.5 million compared to income from continuing operations of $1.0 million in the prior year, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The loss from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses. As previously disclosed, the Company discontinued its PancraGEN ® pancreatic testing business in May 2025 and now operates as a thyroid-only molecular diagn…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
INTERPACE BIOSCIENCES INC
IDXGOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 16, 2026, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended September 30, 2026. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.…
Press release in this filing
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results →Company context
We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.